Antidepressant drug development failed! Neumora's stock price plummeted over 80% in a single day, marking the largest single-day drop since its listing.

The experimental depression medication navacapant did not show significant effects on depression in a clinical trial involving 383 patients, with no significant difference compared to the placebo effect.

cls.cn08:15

U.S. stocks fluctuate丨Neumora surged over 8% in after-hours trading after a failure in the final stage of its experimental depression medication research.

On January 3, Glonghui reported that Neumora Therapeutics (NMRA.US) plummeted 81.42% overnight, followed by an 8.12% increase in after-hours trading, closing at $2.13. Regarding the news, the company announced on Thursday that its experimental drug for treating severe depression showed no efficacy in the final stage of research, as patients receiving navacaprant treatment did not exhibit significant improvements in depression symptom measurements statistically. Neumora is conducting two additional final phase trials for this drug and is developing other medications for brain disorders. (Glonghui)

Gelonghui Finance09:57

Futu Morning News | The first show of the US stock market in the new year was turbulent, with Tesla falling over 6%, dragging down the Nasdaq; is the windfall for nuclear energy coming? AI Nuclear Power Concept stock Constellation rose over 8% against the

The revision of the final value of the USA manufacturing PMI for December releases Bullish Signals; Trump will hold a rally in Washington D.C. on the eve of the presidential inauguration; Tesla's Cybertruck is eligible this year for the maximum $7,500 USA tax credit.

Futu News08:09

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

Businesswire07:40

U.S. Small Caps Close Mixed As Rigetti Computing Lead, Neumora Therapeutics Lags

Dow Jones05:20

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga05:05